MAP2K7 and acute lymphoblastic leukemia: Recent work by Jones et al. shows that MEK plays a key role in drug resistance in relapsed pediatric ALL, and that MEK inhibition can sensitize ALL relapse samples to chemotherapeutics, including methylprednisolone [23].